Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children
Sponsor: Children's Oncology Group
This PHASE3 trial investigates Brain Tumor and Central Nervous System Tumor and is currently completed. Children's Oncology Group leads this study, which shows 13 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Dec 2023 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jul 2017 — Dec 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .